Mednet Logo
Community

When would you ever consider lifelong imatinib in adjuvant therapy for GIST?

Would non-gastric GISTs, high mitotic rate, large size, and young age of patient affect your decision? Especially knowing that TKIs suppress cell growth rather than eradicate disease
1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of Texas MD Anderson Cancer Center
Answered on

The risk of recurrence and mutational status are important tumor related factors. Combine that with host factors including risk tolerance and physical drug tolerance helps with the conversation to reach a unanimous decision.

Join for free or sign in to see the full answer